Abiopharma

ALPHA COGNITION INC. (ACOG)

Symbol	ACOG
Name	ALPHA COGNITION INC.
Sector	UNDEFINED
Region	North America
Industry	Biological Products, (No Diagnostic Substances)
Address	1200-750 W PENDER ST, VANCOUVER, British Columbia, V6C 2T8, Canada
Telephone	(858) 344-4375
Fax	—
Email	—
Website	https://www.alphacognition.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001655923
Description	Alpha Cognition is a biopharmaceutical company dedicated to developing treatments for patients with neurodegenerative diseases. On July 26, 2024, the Company received FDA approval for the Companys New Drug Application (the NDA) for ZUNVEYL® (benzgalantamine) oral tablet for the treatment of mild-to-moderate Alzheimers disease. The Companys focus is on the development of commercial manufacturing and sales of ZUNVEYL. The Company has three additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimers disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (ALPHA-1062IN) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion) and Progranulin GEMs, for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis. Additional info from NASDAQ: Alpha Cognition is a biopharmaceutical company dedicated to developing treatments for patients with neurodegenerative diseases. On July 26, 2024, the Company received FDA approval for the Companys New Drug Application (the NDA) for ZUNVEYL® (benzgalantamine) oral tablet for the treatment of mild-to-moderate Alzheimers disease. The Companys focus is on the development of commercial manufacturing and sales of ZUNVEYL. The Company has three additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimers disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (ALPHA-1062IN) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI; otherwise known as concussion) and Progranulin GEMs, for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis.

2026-09-01 21:00

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-24 18:52

Wills Robert James 🟢 acquired 10.0K shares of Alpha Cognition Inc. (ACOG) at $9.62 Transaction Date: Aug 21, 2026 | Filing ID: 001153

2026-08-13 20:05

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

2026-08-03 12:30

Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update

2026-07-29 12:30

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

2026-07-28 20:05

Opaleye Management Inc. 🟢 acquired 130 shares of Alpha Cognition Inc. (ACOG) at $7.90 Transaction Date: Jul 24, 2026 | Filing ID: 035000

2026-06-29 20:05

Opaleye Management Inc. 🟢 acquired 152.5K shares of Alpha Cognition Inc. (ACOG) at $6.50 Transaction Date: Jun 25, 2026 | Filing ID: 031063

2026-06-29 17:05

New Form SCHEDULE 13G/A - Alpha Cognition Inc. Filed: 2026-06-29 AccNo: 0001493152-26-031066 Size: 23 KB

2026-06-23 14:35

(99% Neutral) ALPHA COGNITION INC. (ACOG) Announces New Board Appointment

2026-06-23 12:30

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board